TG Therapeutics, Inc.
HealthcareNASDAQ:TGTX · NASDAQ Capital Market
+$1.47 today
Vol 2.53M · Avg 2.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
69.0%
avg -192.9%
ROIC
13.5%
avg -119.8%
ROA
42.1%
avg -76.0%
Analysis
ROE is currently the strongest return metric at 69.0% versus its period average of -192.9%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael S. Weiss | Chairman, Chief Executive Officer & President | $2.02M | — | 60 | $9.78M | 6.39% |
Sean A. Power | Chief Financial Officer, Corporate Secretary & Treasurer | $848,500.00 | — | 44 | $798,111.00 | 0.52% |
Adam Waldman | Chief Commercialization Officer | — | — | — | — | — |
Jenna Bosco | Senior Vice President of Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$1.20M
Net Sentiment
$1.20M
Net selling
Most Active
Echelard Yann
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $1.20M over the last 12 months. That adds up to net selling of $1.20M. Echelard Yann was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +100.0% | +90.2% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +100.0% over three years. Forward estimates point to Revenue at +90.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.37B
Alkermes plc
NASDAQ:ALKS
$7.38B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.06B
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.85B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
Who manages TGTX?
TG Therapeutics, Inc. (TGTX) lists 4 active executives. The top listed executive is Michael S. Weiss, Chairman, Chief Executive Officer & President.
Are TGTX insiders buying or selling?
Recent insider activity shows net selling of $22.15M.
Explore More
Continue the stock analysis
Jump to another research area for this company.